CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a ...

Researchers from the Nagoya University Graduate School of Medicine identified an enzyme, alpha-kinase 2 (ALPK2) that is ...

Design Therapeutics' GeneTAC platform is revolutionizing genetic disease treatment with small molecules and promising results ...

The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

The company will use the funding to advance clinical trials for Tune-401, the epigenetic silencing drug for treating chronic ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition ...

Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) closed Jan. 30 at $54.84, up $29.12, or 113%, on what Leerink analyst David ...

Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced promising topline data from the completed Phase 1 clinical trial of its lead mRNA ...

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

Acellera Therapeutics focuses on drug discovery by merging AI-driven innovation with computational scaleability, aiming to ...

Tectonic Therapeutic shares doubled, to $56.80, after the company said it saw positive interim data from a Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, ...